TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07785830: A Clinical Trial to Evaluate the Effects of MK-4646 on Rosuvastatin in Healthy Participants (MK-4646-007)

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$3,454,128

Rescue Site Savings

+$2,280,176

Unlock Full NCT07785830 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07785830 Rescue Dossier →